Palvella Therapeutics, Inc.
PVLA
Rank in Stocks
#5633
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company... Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
Share Price
$142.85
Last synced: 2026-11-20
Market Cap
$2.08B
Change (1 day)
-2.00%
Change (1 year)
51.82%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Palvella Therapeutics, Inc. (PVLA)
Category
Healthcare
Operating Margin for Palvella Therapeutics, Inc. (PVLA)
Operating Margin as of November 2026 TTM: 0.00%
According to Palvella Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Palvella Therapeutics, Inc. from 2020 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | -100.00% |
| 2022 | -167.84% | 1.74% |
| 2021 | -164.97% | 0.00% |
| 2020 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 33.87% | - |
US
|
|
| -116.04% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Palvella Therapeutics, Inc.'s operating margin
What was Palvella Therapeutics, Inc.'s operating margin in 2025?
In 2025, Palvella Therapeutics, Inc.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has Palvella Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Palvella Therapeutics, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2022 (-167.84%).
How does Palvella Therapeutics, Inc.'s operating margin compare with similar companies?
Palvella Therapeutics, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.